Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

IDEV raises $46 mil. for stent trial

You may also be interested in...

Stent Maker MicroPort Scientific Going Public On Hong Kong Exchange

Shanghai-based stent maker MicroPort Scientific is seeking to raise up to $198 million in an initial public offering targeted for Sept. 24 on the Hong Kong stock exchange

Research In Brief

WorldHeart VAD study begins: Pivotal study of the Levacor ventricular assist device as a bridge to cardiac transplantation is under way, with the first successful implant occurring Jan. 13, according to WorldHeart. FDA granted conditional approval to begin the trial, which is ultimately expected to include 160 patients and 10 clinical sites, last August (1"The Gray Sheet" Aug. 24, 2009). Levacor is a bearingless, fully magnetically levitated, implantable centrifugal pump. Thoratec's HeartMate II and HeartMate XVE are the only left ventricular assist devices currently approved for bridge-to-transplant therapy. Thoratec announced last week it had received FDA approval for HeartMate II as a destination therapy, as well

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts